Neovascular age-related macular degeneration Trials in Riga, Latvia
Conditions / Neovascular age-related macular degeneration / Riga, Latvia
Neovascular age-related macular degeneration is a medical condition with active clinical research programs worldwide.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04480463 | A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT04450329 | A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) | COMPLETED | PHASE3 |
| NCT04423718 | Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye | COMPLETED | PHASE3 |
| NCT04757636 | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |
| NCT04864834 | Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration | COMPLETED | PHASE3 |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | COMPLETED | PHASE2 |
| NCT03362190 | ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) | COMPLETED | PHASE2 |
| NCT06680817 | A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | RECRUITING | — |
| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | TERMINATED | PHASE3 |
| NCT03630952 | Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) | TERMINATED | PHASE3 |